<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

6 min read

Anika's Expanding Shoulder Preservation Solutions

10/31/23 9:33 AM

Anika Cheryl Blanchard Interview copy-1Anika’s President and CEO Cheryl Blanchard, Ph.D., discusses the Company’s expanding portfolio of shoulder preservation solutions

Anika Therapeutics entered the Reverse Shoulder Market this year with the US market release of the RevoMotion Reverse Shoulder Arthroplasty System, expanding their complement of products for shoulder joint preservation and replacement. This new offering allows the Company to compete in the rapidly growing US Market for Reverse Shoulders. Lisa Mahan, SmartTRAK Senior Analyst Total Joints & Extremities, talked with Cheryl Blanchard, PhD, President and CEO of Anika, to discuss the launch of RevoMotion, along with the X-Twist Fixation System, Integrity Patch System, Cingal next generation OA injectable and Tactoset Injectable Bone Substitute.
 
The Interview
 

SmartTRAK: RevoMotion has been out almost nine months now in limited release and you just went to full market release. Congratulations. How is that going?

Cheryl Blanchard: Thank you! Anika announced the full market release of the RevoMotion Reverse Shoulder Arthroplasty System (RSA) during the 2023 Orthopaedic Summit (OSET) Annual Meeting September 20-23 in Boston, MA and the response has been overwhelmingly positive.

We began the limited launch in January 2023 and have performed over 100 cases since then. The feedback we received and the response during the limited market release was impressive as some of the first patients in have already returned to their surgeons and asked for the same implant to be placed in their other shoulder. To have patients far enough into recovery to want the RevoMotion RSA in their other shoulder says a lot about the system and its future success. The limited release allowed us to collect feedback to better optimize the instrumentation and surgical technique for the full market release as well. Though we finished gathering feedback months ago, manufacturing instrument sets and system components takes time. That brought us right to our full market release during OSET in September.

We know that the reverse shoulder market is a crowded space. Given that probably 80% of the market is reverse shoulders, for Anika we knew we had something incredible to offer clinicians and patients based on the historic Arthrosurface design philosophies focused on bone sparing, motion preservation and anatomic design features. We also knew that with the data-backed and trusted OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty System, it would be difficult to penetrate the full shoulder arthroplasty market without having a reverse option.

Additionally, there is a big shift of a lot of these products and procedures into the ASC setting. We will possibly see even more products coming into the ASC when CMS changes how they reimburse and we realized that there was a real opportunity to provide optimized instrument trays that would reduce the operating room footprint. RevoMotion has a two-tray instrumentation system that is very streamlined. The surgical technique is also very streamlined. We're hearing great feedback on it and we're excited to be in full market release coming into the fourth quarter.

That's wonderful. You mentioned the instrument trays and some of the design. If there was one thing that differentiates RevoMotion from other reverse shoulders on the market, what would you say that is?

CB: We believe and continue to hear feedback from surgeon users that having the smallest threaded glenoid base plate on the market is one of the biggest differentiators. Personally, I didn't understand the true significance of that until I started to speak directly with surgeons who had used the system. Listening to real-time feedback and observing in the OR, you realize it's a major benefit as it provides ...

To download and read the complete transcript of the interview with Anika’s President & CEO Cheryl Blanchard conducted by Lisa Mahan, VP Product Development & IT, Sr. Analyst TJ&E, just click the button below. Download the Transcript


SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
Lisa Mahan
Written by Lisa Mahan

20+ years' experience in orthopedic industry, including 12 years at J&J DePuy Orthopaedics. Competitive Intelligence Analyst and e-Marketing manager at J&J DePuy Orthopaedics.

  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles